Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Falsification of Data Found on World's 1st Recombinant Human Albumin
April 6, 2009
- REGULATORY NEWS IN BRIEF
April 6, 2009
- LDP's Research Commission Calls For More Investment in Pharma R&D
April 6, 2009
- UGT1A1 Gene Polymorphism Testing Reagent from Sekisui Medical
April 6, 2009
- R&D NEWS IN BRIEF
April 6, 2009
- Meiji Seika Licenses Drug for Schizophrenia from ACADIA
April 6, 2009
- 7th JSMO Annual Meeting
April 6, 2009
- FPMAJ Should Maintain Its Stance Regarding Range of Drugs Eligible for Price Maintenance System: Mr Nagano
March 30, 2009
- Industry Proposes to Create Organization to Develop Unapproved Drugs
March 30, 2009
- REGULATORY NEWS IN BRIEF
March 30, 2009
- Dispensing Fees Will Be Cut if Use of Generics Does Not Increase: Mr Urushibata
March 30, 2009
- GENERICS NEWS IN BRIEF
March 30, 2009
- The First Round Results of GE Amlodipine (1) - Making No Surprise Moves Leads to Success -
March 30, 2009
- Astellas to Enhance Its Presence as "National Flag Pharma"
March 30, 2009
- Astellas, Shionogi Enthusiastic about Joint Research with Academia
March 30, 2009
- Studies Voluntarily Conducted by Physicians Must Be Funded by Contracts
March 30, 2009
- Takara Bio Supplies RetroNectin for 46th Clinical Trial
March 30, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 30, 2009
- JAPhMed to Be Incorporated into Medical Society in April
March 30, 2009
- Takara Bio Licenses LA-PCR Methods to Biotools of Spain
March 30, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…